News

Real-World Study Shows Zanubrutinib Improves Outcomes in Mantle Cell Lymphoma

Treatment /

A real-world study of patients with relapsed or refractory mantle cell lymphoma (MCL) found that the drug Brukinsa may work better than older BTK inhibitors. Researchers reported that patients treated with zanubrutinib in second- or third-line therapy lived longer compared with those treated with Imbruvica. The study also showed that patients taking zanubrutinib went longer […]

Real-World Study Shows Zanubrutinib Improves Outcomes in Mantle Cell Lymphoma Read More »

SurVaxM Vaccine Enters Phase 2 Trial for Neuroendocrine Tumors

Clinical Trails /

MimiVax Inc. and Roswell Park Comprehensive Cancer Center have started a Phase 2 clinical trial to test the cancer vaccine SurVaxM in patients with worsening neuroendocrine tumors (NETs). The study will compare SurVaxM plus the chemotherapy drug temozolomide with temozolomide alone. SurVaxM is designed to help the immune system attack survivin, a protein linked to

SurVaxM Vaccine Enters Phase 2 Trial for Neuroendocrine Tumors Read More »

Experimental Therapy Starves Cancer Cells by Blocking Energy Production

Research Advances /

Researchers have developed an experimental cancer therapy called aurB that kills tumors by blocking their energy production. Inspired by bacteria living inside tumors, scientists created aurB from a bacterial protein called auracyanin. The therapy targets mitochondria, the cell’s energy source, and blocks ATP synthase, an enzyme needed to produce energy. Without energy, cancer cells struggle

Experimental Therapy Starves Cancer Cells by Blocking Energy Production Read More »

New Targeted ADC Therapies Show Promise in Advanced Lung Cancer Treatment

Targeted Therapy /

Antibody-drug conjugates (ADCs) are changing the treatment of advanced non-small cell lung cancer (NSCLC) by delivering chemotherapy directly to cancer cells while reducing damage to healthy tissue. Doctors say these targeted therapies are showing better results than traditional second-line chemotherapy such as docetaxel, which has limited response rates. Medical oncologist Judy Wang explained that ADCs

New Targeted ADC Therapies Show Promise in Advanced Lung Cancer Treatment Read More »

Cancer Experts Warn Biotin Supplements May Interfere With Critical Blood Tests

Research Advances /

Doctors are warning cancer patients to be cautious about taking biotin supplements for hair and nail growth because the vitamin can interfere with important blood tests. Although biotin, also known as vitamin B7, is often promoted online as a harmless beauty supplement, experts say it can create misleading lab results that may affect cancer care.

Cancer Experts Warn Biotin Supplements May Interfere With Critical Blood Tests Read More »

New Lipid Profiling Method Shows Promise for Early Pancreatic Cancer Detection

Research Advances /

Researchers have developed a new lipid analysis method that could improve early detection of pancreatic cancer by identifying hidden changes in blood fat molecules. The technique combines advanced mass spectrometry with specialized software to detect detailed lipid structures that standard tests often miss. The study analyzed 15 lipid classes, including ceramides and sphingomyelins, using a

New Lipid Profiling Method Shows Promise for Early Pancreatic Cancer Detection Read More »

FDA Approves Bizengri for Rare NRG1-Positive Bile Duct Cancer

Drug Approvals /

The FDA has approved Zenocutuzumab (Bizengri) for adults with advanced bile duct cancer linked to rare $NRG1$ gene fusions after previous treatments stopped working. The approval gives a new option to patients with this ultra-rare form of cholangiocarcinoma, a cancer that usually has very limited treatment choices. The decision was based on results from the

FDA Approves Bizengri for Rare NRG1-Positive Bile Duct Cancer Read More »

rintatolimod Combination Shows Strong Results in Recurrent Ovarian Cancer Trial

Clinical Trails /

Updated Phase 2 trial results showed that combining rintatolimod with Pembrolizumab and cisplatin may greatly improve outcomes for patients with platinum-sensitive recurrent ovarian cancer. Among 24 evaluable patients, the treatment achieved a 50% objective response rate, including 5 complete responses. This was much higher than the response rate previously seen with pembrolizumab alone. The clinical benefit

rintatolimod Combination Shows Strong Results in Recurrent Ovarian Cancer Trial Read More »

detalimogene voraplasmid Shows Strong Responses in High-Risk Bladder Cancer Trial

Clinical Trails /

Updated interim results from the Phase 2 LEGEND trial show that detalimogene voraplasmid may be an effective treatment for patients with high-risk, BCG-unresponsive non–muscle invasive bladder cancer (NMIBC). The therapy is delivered directly into the bladder to trigger a local immune response against tumors. The study showed that 54% of patients achieved a complete response

detalimogene voraplasmid Shows Strong Responses in High-Risk Bladder Cancer Trial Read More »

Daraxonrasib Shows Major Survival Benefit in RAS-Mutated Pancreatic Cancer

Treatment /

Daraxonrasib has shown promising results in patients with previously treated RAS-mutated pancreatic ductal adenocarcinoma (PDAC), according to a Phase 1/2 study published in the New England Journal of Medicine. The drug works by blocking the active “ON” state of RAS proteins, helping stop cancer growth signals. In second-line treatment, patients with RAS G12 mutations achieved

Daraxonrasib Shows Major Survival Benefit in RAS-Mutated Pancreatic Cancer Read More »